CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Urigen Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Urigen Pharmaceuticals Inc
501 Silverside Rd Ste 95
Phone: (925) 280-2861p:925 280-2861 WILMINGTON, DE  19809-1376  United States Fax: (925) 280-2861f:925 280-2861

Urigen Pharmaceuticals Inc filed a Registration Withdrawal Request of its Form S-1 (File No. 333-202034) with the SEC on 5/4/2015.
This company is no longer actively traded on any major stock exchange.

Business Summary
Urigen Pharmaceuticals, Inc. (Urigen) is a specialty pharmaceutical company engaged in the development and commercialization of therapeutic products for urological disorders. The Company’s product pipeline includes URG101, for the treatment of Painful Bladder Syndrome (PBS), which has completed a Phase II double blinded, placebo controlled, multi-center trial, and URG301, targeting urethritis and nocturia. Urigen specializes in the development of products for patients with urological ailments including, specifically, the development of products for amelioration Painful Bladder Syndrome/Interstitial Cystitis (PBS or PBS/IC), Urethritis, Nocturia and Overactive Bladder (OAB). Urology represents a specialty pharmaceutical market of approximately 12,000 physicians in North America. Urologists treat a variety of ailments of the urinary tract including urinary tract infections, bladder cancer, overactive bladder, urgency and incontinence and interstitial cystitis, a subset of PBS.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20106/30/2010YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Secretary Dan B.Vickery 48 4/26/2011 1/8/2010
Chief Medical Officer, Director C. Lowell L.Parsons 68 7/6/2010 7/13/2007

Business Names
Business Name
Urigen Pharmaceuticals, Inc.
Urigen, N.A., Inc.

General Information
Number of Employees: 2 (As of 6/30/2010)
Outstanding Shares: 92,221,661 (As of 8/8/2012)
Shareholders: 377
Stock Exchange: NASD
Federal Tax Id: 943156660
Fax Number: (925) 280-2861
Email Address: bweintraub@valentis.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023